AU2002223708A1 - Anti-inflammatory agents - Google Patents

Anti-inflammatory agents

Info

Publication number
AU2002223708A1
AU2002223708A1 AU2002223708A AU2370802A AU2002223708A1 AU 2002223708 A1 AU2002223708 A1 AU 2002223708A1 AU 2002223708 A AU2002223708 A AU 2002223708A AU 2370802 A AU2370802 A AU 2370802A AU 2002223708 A1 AU2002223708 A1 AU 2002223708A1
Authority
AU
Australia
Prior art keywords
inflammatory agents
inflammation
prevention
treatment
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002223708A
Inventor
Heimo Haikala
Minja Hyttila-Hopponen
Kari Lonnberg
Erkki Nissinen
Aino Pippuri
Minna Ruotsalainen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of AU2002223708A1 publication Critical patent/AU2002223708A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

The use of mitochondrial KATP channel openers, particularly compounds of general formula (I), for the treatment or prevention of inflammation by inducing apoptosis of inflammatory cells.
AU2002223708A 2000-11-17 2001-11-16 Anti-inflammatory agents Abandoned AU2002223708A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20002525 2000-11-17
FI20002525A FI20002525A (en) 2000-11-17 2000-11-17 Anti-inflammatory substances
PCT/FI2001/001000 WO2002040025A1 (en) 2000-11-17 2001-11-16 Anti-inflammatory agents

Publications (1)

Publication Number Publication Date
AU2002223708A1 true AU2002223708A1 (en) 2002-05-27

Family

ID=8559519

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002223708A Abandoned AU2002223708A1 (en) 2000-11-17 2001-11-16 Anti-inflammatory agents

Country Status (11)

Country Link
US (1) US6878702B2 (en)
EP (1) EP1341539B1 (en)
JP (1) JP4309652B2 (en)
AT (1) ATE294581T1 (en)
AU (1) AU2002223708A1 (en)
CA (1) CA2429109C (en)
DE (1) DE60110628T2 (en)
ES (1) ES2240564T3 (en)
FI (1) FI20002525A (en)
PT (1) PT1341539E (en)
WO (1) WO2002040025A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1612204A4 (en) * 2003-03-31 2007-04-11 Daiichi Seiyaku Co Hydrazone derivative
DE10337904A1 (en) * 2003-08-18 2005-03-24 Universität Duisburg-Essen Using apoptosis-inducing or stimulating agent for treating disease, particularly infections or tumors, acts by interaction with mitochondrial potassium channels
UA100126C2 (en) 2007-09-14 2012-11-26 Аддекс Фарма С.А. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
CN112500353B (en) * 2020-12-08 2022-11-25 北京晨光同创医药研究院有限公司 Levosimendan prodrug compound, preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185332A (en) * 1989-02-11 1993-02-09 Orion-Yhtyma Oy Thiadiazines and pharmaceutical compositions thereof as well as method of use
GB8903130D0 (en) * 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
US6183948B1 (en) * 1998-04-15 2001-02-06 Johns Hopkins University Methods to identify compounds affecting mitochondria

Also Published As

Publication number Publication date
US20040029870A1 (en) 2004-02-12
WO2002040025A1 (en) 2002-05-23
FI20002525A0 (en) 2000-11-17
JP4309652B2 (en) 2009-08-05
CA2429109A1 (en) 2002-05-23
ATE294581T1 (en) 2005-05-15
CA2429109C (en) 2010-02-16
ES2240564T3 (en) 2005-10-16
JP2004520278A (en) 2004-07-08
DE60110628D1 (en) 2005-06-09
EP1341539B1 (en) 2005-05-04
DE60110628T2 (en) 2006-01-19
EP1341539A1 (en) 2003-09-10
PT1341539E (en) 2005-07-29
US6878702B2 (en) 2005-04-12
FI20002525A (en) 2002-05-18

Similar Documents

Publication Publication Date Title
AU1617901A (en) Urea derivatives as anti-inflammatory agents
NZ506329A (en) Inhibitors of phospholipase enzymes
WO2005051300A3 (en) Bicyclic inhibitors of mek and methods of use thereof
NO20053042L (en) Use of spongosine (2-methoxyadenosine) for the treatment of pain, especially hyperalgesia.
ECSP045104A (en) LIGANDS OF THE CANNABINOID RECEIVERS
AU2002246728A1 (en) Carboline derivatives
EP1508570A4 (en) Novel physiolgically active substances
AU2002249890A1 (en) Carboline derivatives
PE20030061A1 (en) 1-BIARIL-1,8-NAPHTHYRIDIN-4-ONA AS PHOSPHODIESTERASE-4 INHIBITORS
AU1044500A (en) Imidazonaphthyridines
AU2003290592A1 (en) Antitumor benzoylsulfonamides
DE69823493D1 (en) TETRAHYDROPYRIDOVERBINDUNGEN
DK0869965T3 (en) Steroid nitrite ester derivatives useful as anti-inflammatory drugs
SE9801494D0 (en) Novel use
MXPA03001081A (en) Anti-inflammatory medicament.
BRPI0415390A (en) Substituted pyrazinone compounds for the treatment of inflammation
NO20090392L (en) Penem promotions
AU2002223708A1 (en) Anti-inflammatory agents
CA2441461A1 (en) Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia
MY128164A (en) Compounds
AR022321A1 (en) USEFUL ANTI-CONVULSIVE DERIVATIVES FOR THE TREATMENT OF TRANSFORMED MIGRANE
DK0671387T3 (en) New use of 1alfa-fluoro-25-hydroxy-16-en-23-yn-cholecalciferol
CA2267165A1 (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis
MXPA05001469A (en) Use of fermented wheat germ extract as anti-inflammatory agent.
ATE374614T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING CALCITRIOL AND CLOBETASOL PROPIONATE